Introduction
============

Bronchodilators are the cornerstone of maintenance therapy for COPD,[@b1-copd-13-2969] one of the leading causes of mortality and morbidity worldwide.[@b2-copd-13-2969] Combined treatment with a long-acting muscarinic antagonist (LAMA) and a long-acting β~2~-agonist (LABA) plays an important role in the stepwise management of COPD.[@b3-copd-13-2969] The Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends combined LAMA/ LABA treatment as a first-line therapy for patients with COPD in GOLD group D; and as a step-up treatment for patients in GOLD group C who experience frequent exacerbations despite LAMA or LABA monotherapy, and patients in GOLD group B who experience persistent symptoms despite bronchodilator monotherapy.[@b1-copd-13-2969]

Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 18/9.6 μg (Bevespi Aerosphere^®^; AstraZeneca, Wilmington, DE, USA) is a fixed-dose combination (FDC) of the LAMA glycopyrrolate (GP) and the LABA formoterol fumarate (FF), formulated using innovative co-suspension delivery technology. GFF MDI is approved in the USA for the long-term maintenance treatment of airflow obstruction in patients with COPD[@b4-copd-13-2969] and, to date, is the first and only LAMA/LABA FDC available as an MDI.

The efficacy and safety of GFF MDI compared with respective monocomponents have been demonstrated over a period of up to 52 weeks in the pivotal Phase III studies PINNACLE-1, PINNACLE-2 (24 weeks; NCT01854645 and NCT01854658), and PINNACLE-3 (28-week safety extension study; NCT01970878), in patients from the USA, Australia, and New Zealand.[@b5-copd-13-2969],[@b6-copd-13-2969] Due to differences in COPD prevalence and burden between different countries and regions,[@b7-copd-13-2969]--[@b10-copd-13-2969] as well as potential differences in the observed effects of pharmacological therapies,[@b11-copd-13-2969] it was deemed important to evaluate the efficacy and safety of COPD maintenance treatments in other geographical patient populations. Here, we present the results of the PINNACLE-4 study ([ClinicalTrials.gov](http://ClinicalTrials.gov): NCT02343458), which investigated the efficacy and safety of GFF MDI compared to its mono-components (GP MDI and FF MDI) and placebo MDI in a population with moderate-to-very severe COPD, which included Asian and European patients.

Methods
=======

Study design and treatment
--------------------------

PINNACLE-4 was a randomized, double-blind, parallel-group, placebo-controlled Phase III study conducted at multiple sites across Asia, Europe, and the USA. Patients were randomized 7:6:6:3 using an Interactive Web Response System (further details in the Supplementary materials) to receive treatment with GFF MDI 18/9.6 μg (equivalent to glycopyrronium/formoterol fumarate dihydrate 14.4/10 μg), GP MDI 18 μg, FF MDI 9.6 μg, or matched placebo MDI (all twice daily) for 24 weeks, with randomization stratified by reversibility to rescue albuterol sulfate and by COPD disease severity. Patients provided written informed consent prior to screening, and the study was conducted in accordance with Good Clinical Practice, including the Declaration of Helsinki and the International Council for Harmonisation. The protocol was approved by local institutional review boards ([Table S1](#SD1-copd-13-2969){ref-type="supplementary-material"}). Patients were required to discontinue prohibited COPD medications (including oral β~2~-agonists, LABAs, cromoglycate or nedocromil inhalers, leukotriene antagonists, ketotifen \[except as eye drops\], and LAMAs) following screening and were switched to sponsor-provided ipratropium bromide (administered four times daily) and albuterol sulfate (as needed) to control symptoms during the screening period. Patients using a maintenance FDC of an inhaled corticosteroid (ICS) and a LABA discontinued this, and were switched to the corresponding ICS monotherapy (fluticasone, mometasone, or budesonide) at an equivalent dose, as well as ipratropium bromide and albuterol sulfate (providing they had been maintained on a stable dose of the ICS component for ≥4 weeks prior to screening). Any patients taking a maintenance dose of an ICS not administered as an FDC with a LABA were allowed to continue using the ICS if they had been on a stable dose for ≥4 weeks prior to screening. Ipratropium bromide was discontinued after screening. Sponsor-provided albuterol sulfate was permitted, as needed, for the relief of symptoms throughout the study.

Study population
----------------

Patients were 40--80 years of age and had an established clinical history of COPD as defined by the American Thoracic Society/European Respiratory Society.[@b12-copd-13-2969] Inclusion and exclusion criteria were the same as reported for PINNACLE-1 and PINNACLE-2.[@b5-copd-13-2969] Briefly, eligible patients were current or former smokers (≥10 pack-years) with an FEV~1~/forced vital capacity ratio of, \<0.70 and an FEV~1~ of ,\<80% predicted normal value at screening. Further details are provided in the Supplementary materials. Patients were required to demonstrate stable baseline FEV~1~, ie, mean predose FEV~1~ at randomization within ±20% or 200 mL of the mean of the predose FEV~1~ assessment obtained at the previous two screening visits. The ability of patients to use the MDI correctly was confirmed at screening, with additional training provided as necessary.

Assessments
-----------

The primary objective of the study was to compare the efficacy of GFF MDI with its monocomponents (GP MDI and FF MDI) and placebo MDI and also GP MDI and FF MDI with placebo MDI, in patients with moderate-to-very severe COPD. Study endpoints differed according to the regional regulatory registration requirements. This manuscript reports the approach that satisfies the filing requirements of the US and China regulatory authorities. Data for similar approaches and endpoints satisfying the filing requirements of other regions were also generated. The change from baseline in morning predose trough FEV~1~ at Week 24 was the primary endpoint. Secondary lung function endpoints included change from baseline in morning predose trough FEV~1~ over 24 weeks, peak change from baseline in FEV~1~ within 2 hours postdosing at Week 24, and time to onset of action on Day 1 (defined as the first time point at which the difference from placebo MDI was statistically significant).

Other secondary endpoints included Transition Dyspnea Index (TDI) focal score over 24 weeks, change from baseline in St George's Respiratory Questionnaire (SGRQ) total score at Week 24 (intent-to-treat \[ITT\] population and symptomatic population), and change from baseline in mean daily rescue medication use over 24 weeks (rescue medication user population). Assessments of TDI focal score at Week 24 and SGRQ score over Weeks 12--24 were additional endpoints. Baseline Dyspnea Index (BDI) and TDI were assessed using the interviewer-administrated version of the BDI/TDI questionnaire.[@b13-copd-13-2969],[@b14-copd-13-2969] Other efficacy endpoints included responder analyses to determine the proportion of patients achieving an improvement of the minimal clinically important difference (MCID) threshold of ≥1 unit in TDI focal score[@b15-copd-13-2969] over 24 weeks and ≥4 units in SGRQ score[@b16-copd-13-2969] at Week 24.

Safety assessments included electrocardiograms (ECGs), clinical laboratory testing, and vital sign measurements. Adverse events (AEs) were monitored throughout the study.

Statistical analysis
--------------------

Unless otherwise specified, results were based on analyses using the ITT population (all patients who were randomized and received any study treatment, even if, \<1 full dose). The safety population was the same as the ITT population, except patients who were analyzed according to treatment received rather than treatment assigned. The symptomatic population included all patients in the ITT population with a COPD assessment test (CAT) score of ≥15 at screening. The rescue medication user population included all patients in the ITT population with the mean baseline rescue medication use (albuterol sulfate) of ≥1 puff/day (calculated from the last 7 days of the 10--14 days screening period).

A sample size of 1,614 patients was estimated to provide 91% of power to detect differences for all primary comparisons (GFF MDI vs placebo MDI and each monocomponent and each monocomponent vs placebo MDI) in the primary endpoint (change from baseline in morning predose trough FEV~1~ at Week 24) with Type I error controlled at a two-sided α level of 0.05. The same sample size was estimated to provide 99% of power to detect differences for the same comparisons for change from baseline in morning predose trough FEV~1~ over 24 weeks.

The primary and secondary endpoints (with the exception of time to onset of action) were analyzed using repeated measures linear models (further details in the Supplementary materials). Strong control of Type I error (two-sided α=0.05) was implemented sequentially across the five key comparisons for the primary endpoint and then simultaneously across the secondary endpoints within a key comparison using the Hochberg procedure (two-sided α=0.05).

Results
=======

Patient disposition
-------------------

A total of 1,756 patients were randomized and received treatment (714 patients from Asia, 496 patients from the USA, and 546 patients from Europe \[including Russia\]), and 1,528 (87%) patients completed the study ([Figure 1](#f1-copd-13-2969){ref-type="fig"}). The ITT and safety populations included 1,740 patients, of whom 841 patients were symptomatic (baseline CAT score ≥15). The rescue medication user population comprised 822 patients. Patient demographics and baseline characteristics are summarized in [Table 1](#t1-copd-13-2969){ref-type="table"}. The mean age of the patient was 64.2 years, 74.1% of them were male, and 40.2% of them were Asian (56.7% White).

Efficacy
--------

For the primary endpoint of change from baseline in morning predose trough FEV~1~ at Week 24, treatment with GFF MDI resulted in significantly greater improvements vs placebo MDI (least squares mean \[LSM\] difference: 165 mL; *P*\<0.0001; [Figure 2](#f2-copd-13-2969){ref-type="fig"} and [Table 2](#t2-copd-13-2969){ref-type="table"}), GP MDI (LSM difference: 59 mL; *P*\<0.0001), and FF MDI (LSM difference: 72 mL; *P*\<0.0001). GP MDI and FF MDI treatments significantly increased morning predose trough FEV~1~ at Week 24 compared to placebo MDI (LSM difference 105 and 92 mL, respectively; both *P*\<0.0001; [Figure 2](#f2-copd-13-2969){ref-type="fig"}).

Similar improvements as for the primary endpoint were observed for change from baseline in morning predose trough FEV~1~ over 24 weeks ([Figure 2](#f2-copd-13-2969){ref-type="fig"} and [Table 2](#t2-copd-13-2969){ref-type="table"}). GFF MDI led to significant improvements in peak change from baseline in FEV~1~ within 2 hours postdose at Week 24 compared to GP MDI, FF MDI, and placebo MDI ([Table 2](#t2-copd-13-2969){ref-type="table"}). Onset of action for GFF MDI, GP MDI, and FF MDI occurred within 5 minutes postdose (LSM differences vs placebo MDI 179 mL \[*P*\<0.0001\], 37 mL \[*P*=0.0002\], and 164 mL \[*P*\<0.0001\], respectively).

Significant improvements in TDI focal score over 24 weeks and SGRQ score at Week 24 were observed in both the ITT population and the symptomatic population following treatment with GFF MDI compared with GP MDI and placebo MDI (*P*\<0.05) but not with FF MDI ([Table 3](#t3-copd-13-2969){ref-type="table"}). Improvements in TDI score at Week 24 and SGRQ score over Weeks 12--24 were also greater following GFF MDI treatment compared to GP MDI and placebo MDI in both populations ([Table S2](#SD2-copd-13-2969){ref-type="supplementary-material"}). Patients treated with GFF MDI were more likely to achieve an improvement in at least the MCID for TDI score (≥1.0 unit) and SGRQ score (≥4.0 unit decrease) vs placebo MDI and versus GP MDI for TDI score (ITT population and symptomatic population; [Table 4](#t4-copd-13-2969){ref-type="table"}). Significant improvements in rescue medication use were observed for GFF MDI vs GP MDI (LSM difference: −0.77; *P*=0.0001) and placebo MDI in the rescue medication user population (LSM difference: −0.98; *P*\<0.0001; [Table 3](#t3-copd-13-2969){ref-type="table"}).

Safety
------

The incidence of treatment-emergent AEs (TEAEs), treatment-related TEAEs, serious TEAEs, or TEAEs leading to discontinuation was similar across treatment groups ([Table 5](#t5-copd-13-2969){ref-type="table"}), with the majority of TEAEs being mild or moderate and not considered related to study treatment. A relatively low proportion of patients (ranging from 4.3% with placebo MDI to 5.3% with GP MDI) discontinued due to TEAEs. The most commonly reported TEAEs included upper respiratory tract infection, worsening of COPD, headache, and hypertension ([Table 5](#t5-copd-13-2969){ref-type="table"}).

One death occurred in each of the treatment groups (lung cancer \[metastatic; n=1 with both GFF MDI and placebo MDI\], hemorrhagic stroke \[GP MDI\], and hypoglycemic coma \[FF MDI\]). None of these deaths were judged by the investigator to be related to study drug treatment.

Discussion
==========

Treatment with the LAMA/LABA FDC, GFF MDI, improved lung function compared to placebo MDI and mono-components and improved symptoms and patient-reported outcomes compared to placebo MDI and GP MDI in a population of patients with moderate-to-very severe COPD from Asia, Europe, and the USA. Improvements in the primary endpoint -- change from baseline in morning predose trough FEV~1~ at Week 24 -- exceeded the MCID of 100 mL[@b17-copd-13-2969] for both GFF MDI and GP MDI vs placebo MDI and were significantly higher following treatment with GFF MDI vs monocomponents. Overall, results confirmed those from previous Phase III studies, which showed GFF MDI to be efficacious and well tolerated in a population that included patients from the USA, Australia, and New Zealand.[@b5-copd-13-2969],[@b6-copd-13-2969]

Improvements in the secondary lung function endpoint (peak change from baseline in FEV~1~ within 2 hours postdose at Week 24) as well as rescue medication use were significantly larger in the GFF MDI treatment arm vs monocom-ponents and placebo MDI and similar to those observed in PINNACLE-1 and PINNACLE-2.[@b5-copd-13-2969],[@b18-copd-13-2969] TDI focal scores indicated greater reductions in breathlessness following GFF MDI treatment than comparators, although treatment differences were only significant compared with GP MDI and placebo MDI (ITT and symptomatic populations). The treatment difference for GFF MDI vs placebo MDI in TDI score over 24 weeks was larger than that observed in PINNACLE-1 and PINNACLE-2, which may be in part due to differences in the method of assessment of TDI score (the interviewer-administered version of the TDI was used in this study vs the self-administered, computerized version used in PINNACLE-1 and PINNACLE-2).[@b19-copd-13-2969] A larger proportion of patients in the GFF MDI group achieved a clinically relevant improvement in TDI (total score ≥1 unit)[@b15-copd-13-2969] vs GP MDI and placebo MDI in the symptomatic and ITT populations, demonstrating that GFF MDI was effective in reducing breathlessness in patients with COPD. The results of the SGRQ assessment in this study suggest that GFF MDI may improve health-related quality of life (HRQoL) compared with placebo MDI and GP MDI, which is consistent with the results of PINNACLE-1.[@b5-copd-13-2969],[@b18-copd-13-2969] Although the improvements seen with GFF MDI in patient-reported outcomes (TDI and SGRQ) were not statistically significant vs FF MDI, both treatments were effective in improving symptoms vs placebo. Differences between active treatments for patient-reported outcomes can be small and, therefore, these outcome measures may not be sensitive in indicating differences between active treatments. Ultimately, the superior effects of GFF MDI vs FF MDI on lung function may result in greater benefits for patients' quality of life when sustained over a longer time period than the 24-week duration of the current study. In the long-term PINNACLE-3 safety study, treatment with GFF MDI resulted in statistically significant improvements in TDI score and numerical improvements in SGRQ, over 52 weeks compared with FF MDI.[@b6-copd-13-2969]

Although no head-to-head comparisons between GFF MDI and other LAMA/LABA FDCs have been reported, the magnitude of improvements in lung function, rescue medication use, and HRQoL vs monocomponents observed in this study followed a similar trend to those of pivotal studies with other LAMA/LABA FDCs.[@b20-copd-13-2969]--[@b27-copd-13-2969] While several other efficacious and well-tolerated LAMA/LABA FDC combinations are available for the maintenance treatment of COPD, GFF MDI is notably the first to be delivered using an MDI. The co-suspension delivery technology used to formulate GFF MDI overcame formulation challenges encountered with MDIs,[@b28-copd-13-2969] resulting in consistent in vitro aerosol performance, even in the presence of simulated patient-handling errors,[@b29-copd-13-2969] providing reliable drug dose delivery to all regions of the lungs with high efficiency.[@b30-copd-13-2969] As familiarity with an inhaler can result in more favorable clinical outcomes in respiratory disease[@b31-copd-13-2969],[@b32-copd-13-2969] and MDIs remain a commonly prescribed device type for rescue medication,[@b33-copd-13-2969] the availability of a LAMA/LABA FDC delivered by MDI offers a useful option for the maintenance treatment of COPD. A Phase III study has shown that the addition of a spacer does not affect the lung function benefits and tolerability of GFF MDI,[@b35-copd-13-2969] suggesting that this FDC could be a treatment option for patients who require a spacer to compensate for poor hand-to-breath coordination with an MDI.

A potential limitation of this study was the short duration (6 months) relative to expected use as prophylactic therapy. However, the long-term safety and efficacy of GFF MDI have been evaluated over a 1-year period during the PINNACLE-3 safety extension study.[@b6-copd-13-2969] Additionally, patients could have potentially perceived benefit from participation in a study of the novel co-suspension delivery technology MDI. However, placebo was delivered by the same device as the active treatments to control for effects due to patient perception. The strength of this study was that patients were enrolled from sites across Asia, Europe, and the USA, allowing the efficacy and safety of GFF MDI to be evaluated in patients from a broad range of geographical locations and socioeconomic backgrounds. Patients were not required to be symptomatic at baseline for enrollment, though results were analyzed in a subgroup of patients with a CAT score of ≥15 (48% of patients randomized), which provided an insight into the efficacy of GFF MDI in symptomatic patients.

Conclusion
==========

The results of PINNACLE-4 demonstrate that GFF MDI improves lung function, symptoms, and patient-reported outcomes in a study population including patients from Asia, Europe, and the USA. These results are consistent with previous Phase III studies with GFF MDI, which showed that this LAMA/LABA FDC was efficacious and well tolerated with no unexpected safety signals in patients with moderate-to-very severe COPD.

Data sharing statement
======================

All relevant data analyzed during this study are included in this article.

Supplementary materials
=======================

Study design and inclusion/exclusion criteria
---------------------------------------------

A randomization ratio of 7:6:6:3 was used, as initial modeling suggesting that this is the most efficient for the sample size and treatments in this study. The appropriateness of this ratio was confirmed by the results of PINNACLE-1 and PINNACLE-2.[@b37-copd-13-2969]

Patients were 40--80 years of age, had an established clinical history of COPD as defined by the American Thoracic Society/European Respiratory Society,[@b38-copd-13-2969] and were current or former smokers with a history of at least 10 pack-years. COPD had to be of at least moderate severity,[@b39-copd-13-2969] defined as a FEV~1~/forced vital capacity ratio of \<0.70 at screening, and FEV~1~ \<80% predicted normal value (calculated using the Third National Health and Nutrition Examination Survey[@b40-copd-13-2969] or local reference equations applicable to other regions) and ≥750 mL if FEV~1~ \<30% predicted normal (ie, very severe COPD).

Exclusion criteria included diagnosis of a significant disease other than COPD (which, in the opinion of the investigator, could put the patient at risk or could influence either the study results or the patient's ability to participate); poorly controlled COPD (defined as acute worsening of COPD that required treatment with oral corticosteroids or antibiotics within 6 weeks of, or during, screening); and hospitalization due to poorly controlled COPD within 3 months prior to, or during, screening. The need for long-term oxygen therapy(\>12 hour/day), change in smoking status within 6 weeks of or during screening, and poor hand-to-breath coordination (requiring the use of a spacer device with an MDI) were also exclusion criteria.

Statistical analysis
--------------------

The primary endpoint was analyzed using a repeated measures linear model with baseline FEV~1~ (the mean of evaluable 60- and 30-minute predose values on Day 1) and reversibility to albuterol sulfate as continuous covariates and visit, treatment, and treatment-by-visit interaction as categorical covariates. An unstructured variance--covariance matrix was applied, and two-sided *P*-values and point estimates with two-sided 95% CIs were produced for each treatment difference. Treatment group comparisons for the secondary endpoints were evaluated using a similar repeated measures linear model as for the primary endpoint but included the relevant baseline covariate for each endpoint. Time to onset of action on Day 1 was determined for each treatment using the 5 and 15-minute postdosing FEV~1~ assessments and analyzed using an analysis of covariance model, with baseline FEV~1~ and reversibility to albuterol sulfate as continuous covariates. For Transition Dyspnea Index and St George's Respiratory Questionnaire responder analyses, logistic regression was used to compare treatment groups and *P*-values and odds ratios with 95% CIs were produced for each comparison. The procedure to control Type I error was applied to primary and secondary endpoints only and is described in the main body of the article.
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###### 

Additional patient-reported outcome endpoints (ITT population, unless stated otherwise)

                                                                                                                                                                                 GFF MDI 18/9.6 μg   GP MDI 18 μg           FF MDI 9.6 μg         Placebo MDI
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------- ---------------------- --------------------- ----------------------
  TDI focal score at Week 24                                                                                                                                                                                                                      
   n                                                                                                                                                                             487                 410                    413                   196
   LSM                                                                                                                                                                           1.8                 1.4                    1.6                   0.9
   SE                                                                                                                                                                            0.12                0.13                   0.13                  0.19
  Treatment difference for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                              
   LSM (95% CI)                                                                                                                                                                  NA                  0.41 (0.06, 0.75)      0.20 (−0.15, 0.55)    0.90 (0.46, 1.34)
   *P*-value                                                                                                                                                                     NA                  0.0229                 0.2659                \<0.0001
  TDI focal score at Week 24 (symptomatic population)[a](#tfn28-copd-13-2969){ref-type="table-fn"}                                                                                                                                                
   n                                                                                                                                                                             219                 201                    188                   91
   LSM                                                                                                                                                                           1.7                 1.1                    1.6                   0.8
   SE                                                                                                                                                                            0.19                0.20                   0.20                  0.29
  Treatment difference for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                              
   LSM (95% CI)                                                                                                                                                                  NA                  0.63 (0.10, 1.17)      0.11 (−0.43, 0.66)    0.87 (0.19, 1.55)
   *P*-value                                                                                                                                                                     NA                  0.0202                 0.6879                0.0122
  Change from baseline in SGRQ total score over 12--24 weeks[b](#tfn29-copd-13-2969){ref-type="table-fn"}                                                                                                                                         
   n                                                                                                                                                                             516                 436                    436                   205
   LSM                                                                                                                                                                           −5.2                −3.6                   −5.0                  −1.7
   SE                                                                                                                                                                            0.46                0.50                   0.50                  0.72
  Treatment difference for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                              
   LSM (95% CI)                                                                                                                                                                  NA                  −1.62 (−2.94, −0.30)   −0.27 (−1.59, 1.05)   −3.50 (−5.18, −1.82)
   *P*-value                                                                                                                                                                     NA                  0.0165                 0.6908                \<0.0001
  Change from baseline in SGRQ total score over 12--24 weeks[b](#tfn29-copd-13-2969){ref-type="table-fn"}(symptomatic population)[a](#tfn28-copd-13-2969){ref-type="table-fn"}                                                                    
   n                                                                                                                                                                             237                 218                    200                   97
   LSM                                                                                                                                                                           −6.9                −3.9                   −7.3                  −3.1
   SE                                                                                                                                                                            0.76                0.79                   0.83                  1.19
  Treatment difference for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                              
   LSM (95% CI)                                                                                                                                                                  NA                  −2.99 (−5.15, −0.84)   0.32 (−1.89, 2.53)    −3.83 (−6.60, −1.06)
   *P*-value                                                                                                                                                                     NA                  0.0066                 0.7787                0.0068

**Notes:**

The symptomatic population was defined as patients in the ITT population with a COPD assessment test score ≥15 at baseline (screening).

SGRQ score over 12--24 weeks was based on assessments at Weeks 12, 16, 20, and 24.

**Abbreviations:** FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; ITT, intent to treat; LSM, least squares mean; MDI, metered dose inhaler; NA, not applicable; SE, standard error; SGRQ, St George's Respiratory Questionnaire; TDI, Transition Dyspnea Index.
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AE

:   adverse event

BDI

:   Baseline Dyspnea Index

BMI

:   body mass index

CAT

:   COPD assessment test

ECG

:   electrocardiogram

FDC

:   fixed-dose combination

FF

:   formoterol fumarate

GFF

:   glycopyrrolate/formoterol fumarate

GP

:   glycopyrrolate

HRQoL

:   health-related quality of life

ICS

:   inhaled corticosteroid

ITT

:   intent-to-treat

LABA

:   long-acting β2-agonist

LAMA

:   long-acting muscarinic antagonist

LSM

:   least squares mean

MCID

:   minimum clinically important difference

MDI

:   metered dose inhaler

SE

:   standard error

SGRQ

:   St George's Respiratory Questionnaire

TDI

:   Transition Dyspnea Index

TEAE

:   treatment-emergent adverse event.

![Patient disposition.\
**Note:** ^a^One patient in the GP MDI group completed Week 24 but did not complete the follow-up call (14 days after last study drug dosing), so was categorized as having discontinued the study but was not classed as withdrawing from the study.\
**Abbreviations:** FF, formoterol fumarate; GFF, GP/FF; GP, glycopyrrolate; MDI, metered dose inhaler.](copd-13-2969Fig1){#f1-copd-13-2969}

![LSM change (±SE) from baseline in morning predose trough FEV~1~ over 24 weeks (ITT population).\
**Abbreviations:** FF, formoterol fumarate; GFF, GP/FF; GP, glycopyrrolate; ITT, intent-to-treat; LSM, least squares mean; MDI, metered dose inhaler; SE, standard error.](copd-13-2969Fig2){#f2-copd-13-2969}

###### 

Patient demographics and baseline characteristics (ITT population)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                             GFF MDI\        GP MDI\         FF MDI\         Placebo\
                                                                                             18/9.6 μg\      18 μg\          9.6 μg\         MDI\
                                                                                             (n=551)         (n=474)         (n=480)         (n=235)
  ------------------------------------------------------------------------------------------ --------------- --------------- --------------- ---------------
  Age (years), mean (SD)                                                                     64.7 (7.4)      64.0 (8.1)      64.1 (7.6)      63.9 (7.5)

  Male, n (%)                                                                                408 (74.0)      346 (73.0)      365 (76.0)      171 (72.8)

  Race, n (%)                                                                                                                                

   White                                                                                     315 (57.2)      275 (58.0)      260 (54.2)      137 (58.3)

   Black/African American                                                                    12 (2.2)        18 (3.8)        16 (3.3)        6 (2.6)

   Asian                                                                                     223 (40.5)      181 (38.2)      204 (42.5)      92 (39.1)

   American Indian or Alaska Native                                                          1 (0.2)         0               0               0

  BMI (kg/m^2^), mean (SD)                                                                   26.3 (5.9)      26.5 (5.7)      26.3 (6.2)      26.2 (6.2)

  Smoking status, n (%)                                                                                                                      

   Current                                                                                   252 (45.7)      209 (44.1)      208 (43.3)      113 (48.1)

   Former                                                                                    299 (54.3)      265 (55.9)      272 (56.7)      122 (51.9)

   Number of pack-years smoked,[a](#tfn1-copd-13-2969){ref-type="table-fn"} mean (SD)        45.9 (24.3)     44.8 (25.5)     46.9 (26.1)     45.7 (26.4)

  COPD severity,[b](#tfn2-copd-13-2969){ref-type="table-fn"} n (%)                                                                           

   Mild[c](#tfn3-copd-13-2969){ref-type="table-fn"}                                          6 (1.1)         9 (1.9)         5 (1.0)         6 (2.6)

   Moderate                                                                                  330 (59.9)      283 (59.7)      290 (60.4)      137 (58.3)

   Severe                                                                                    192 (34.8)      168 (35.4)      171 (35.6)      86 (36.6)

   Very severe                                                                               23 (4.2)        14 (3.0)        14 (2.9)        6 (2.6)

  COPD duration (years), mean (SD)                                                           (n=546)\        (n=474)\        (n=477)\        (n=234)\
                                                                                             6.2 (5.9)       6.2 (5.8)       6.1 (6.2)       6.1 (5.6)

  Postbronchodilator FEV~1~ (% predicted), mean (SD)                                         (n=550)\        (n=472)\        (n=480)\        (n=235)\
                                                                                             53.96 (13.73)   54.82 (14.08)   53.92 (13.22)   54.40 (13.90)

  Reversibility to albuterol                                                                                                                 

   Reversible,[d](#tfn4-copd-13-2969){ref-type="table-fn"} n (%)                             249 (45.2)      207 (43.7)      207 (43.1)      108 (46.0)

   Reversibility postbronchodilator for FEV~1~ (%), mean (SD)                                17.5 (15.2)     16.9 (13.8)     17.3 (14.6)     18.1 (15.9)

  Use of ICS,[e](#tfn5-copd-13-2969){ref-type="table-fn"} n (%)                              169 (30.7)      143 (30.2)      142 (29.6)      79 (33.6)

  BDI focal score, mean (SD)                                                                 (n=532)\        (n=457)\        (n=458)\        (n=217)\
                                                                                             6.7 (2.2)       6.7 (2.3)       6.8 (2.2)       6.2 (2.2)

  SGRQ total score, mean (SD)                                                                (n=489)\        (n=412)\        (n=415)\        (n=196)\
                                                                                             40.8 (16.9)     39.4 (17.7)     38.7 (16.9)     41.7 (17.2)

  CAT total score,[f](#tfn6-copd-13-2969){ref-type="table-fn"} mean (SD)                     (n=550)\        (n=472)\        (n=480)\        (n=235)\
                                                                                             14.9 (7.0)      15.2 (7.3)      14.9 (7.0)      15.2 (7.4)

  Rescue medication use[g](#tfn7-copd-13-2969){ref-type="table-fn"} (puffs/day), mean (SD)   (n=256)\        (n=225)\        (n=232)\        (n=109)\
                                                                                             4.3 (3.4)       4.0 (2.7)       4.1 (2.8)       4.1 (2.9)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Number of pack-years smoked = (number of cigarettes each day/20) × number of years smoked.

Severity of COPD was based on the nonmissing postalbuterol assessment at screening.

These patients were characterized as having mild COPD due to the application of an Asian correction factor to baseline lung function assessments at the time of analysis.

Reversible is defined as improvement in FEV~1~ postalbuterol administration compared to the prealbuterol of ≥12% or ≥200 mL.

Defined as using ICS on the day of the first dose of study medication.

CAT total score is the sum of eight CAT item scores (range: 0--40).

Rescue medication use was analyzed in the rescue medication user population, defined as all patients in the ITT population with the mean baseline rescue albuterol sulfate use of ≥1 puff/day.

**Abbreviations:** BDI, Baseline Dyspnea Index; BMI, body mass index; CAT, COPD assessment test; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; ICS, inhaled corticosteroid; ITT, intent-to-treat; MDI, metered dose inhaler; SGRQ, St George's Respiratory Questionnaire.

###### 

Primary and secondary lung function endpoints (ITT population)

                                                                                                                          GFF MDI 18/9.6 μg   GP MDI 18 μg                                           FF MDI 9.6 μg                                          Placebo MDI
  ----------------------------------------------------------------------------------------------------------------------- ------------------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
  **Primary endpoint**                                                                                                                                                                                                                                      
  Change from baseline in morning predose trough FEV~1~ at Week 24 (mL)                                                                                                                                                                                     
   n                                                                                                                      488                 412                                                    413                                                    196
   LSM                                                                                                                    120                 60                                                     47                                                     −45
   SE                                                                                                                     9.1                 9.9                                                    9.9                                                    14.3
  Treatment difference for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                                        
   LSM (95% CI)                                                                                                           NA                  59 (33, 86)                                            72 (46, 99)                                            165 (132, 198)
   *P*-value                                                                                                              NA                  \<0.0001[a](#tfn9-copd-13-2969){ref-type="table-fn"}   \<0.0001[a](#tfn9-copd-13-2969){ref-type="table-fn"}   \<0.0001[a](#tfn9-copd-13-2969){ref-type="table-fn"}
  **Secondary endpoints**                                                                                                                                                                                                                                   
  Change from baseline in morning predose trough FEV~1~ over 24 weeks[b](#tfn10-copd-13-2969){ref-type="table-fn"} (mL)                                                                                                                                     
   n                                                                                                                      541                 465                                                    467                                                    225
   LSM                                                                                                                    135                 80                                                     63                                                     −20
   SE                                                                                                                     7.0                 7.6                                                    7.6                                                    10.9
  Treatment difference for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                                        
   LSM (95% CI)                                                                                                           NA                  55 (35, 76)                                            72 (52, 92)                                            155 (129, 180)
   *P*-value                                                                                                              NA                  \<0.0001[a](#tfn9-copd-13-2969){ref-type="table-fn"}   \<0.0001[a](#tfn9-copd-13-2969){ref-type="table-fn"}   \<0.0001[a](#tfn9-copd-13-2969){ref-type="table-fn"}
  Peak change from baseline in FEV~1~ within 2 hours postdosing at Week 24 (mL)                                                                                                                                                                             
   n                                                                                                                      490                 412                                                    413                                                    196
   LSM                                                                                                                    358                 214                                                    247                                                    55
   SE                                                                                                                     10.2                11.1                                                   11.1                                                   16.0
  Treatment difference for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                                        
   LSM (95% CI)                                                                                                           NA                  145 (115, 174)                                         111 (81, 140)                                          303 (266, 340)
   *P*-value                                                                                                              NA                  \<0.0001[a](#tfn9-copd-13-2969){ref-type="table-fn"}   \<0.0001[a](#tfn9-copd-13-2969){ref-type="table-fn"}   \<0.0001[a](#tfn9-copd-13-2969){ref-type="table-fn"}

**Notes:**

Statistically significant/superior.

Morning predose trough FEV~1~ over 24 weeks was based on assessments at Weeks 2, 4, 8, 12, 16, 20, and 24.

**Abbreviations:** FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; ITT, intent-to-treat; LSM, least squares mean; MDI, metered dose inhaler; NA, not applicable; SE, standard error.

###### 

Secondary patient-reported outcome endpoints (ITT population, unless stated otherwise)

                                                                                                                                                                        GFF MDI 18/9.6 μg   GP MDI 18 μg                                                                                        FF MDI 9.6 μg                                         Placebo MDI
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------- --------------------------------------------------------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------------------------------------------------------
  TDI focal score over 24 weeks[a](#tfn12-copd-13-2969){ref-type="table-fn"}                                                                                                                                                                                                                                                                          
   n                                                                                                                                                                    532                 457                                                                                                 458                                                   217
   LSM                                                                                                                                                                  1.6                 1.3                                                                                                 1.5                                                   0.8
   SE                                                                                                                                                                   0.09                0.10                                                                                                0.10                                                  0.14
  Treatment difference for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                                                                                                                                  
   LSM (95% CI)                                                                                                                                                         NA                  0.33 (0.07, 0.59)                                                                                   0.15 (−0.11, 0.41)                                    0.80 (0.47, 1.13)
   *P*-value                                                                                                                                                            NA                  0.0125[b](#tfn13-copd-13-2969){ref-type="table-fn"}                                                 0.2530                                                \<0.0001[b](#tfn13-copd-13-2969){ref-type="table-fn"}
  TDI focal score over 24 weeks[a](#tfn12-copd-13-2969){ref-type="table-fn"} (symptomatic population)[c](#tfn14-copd-13-2969){ref-type="table-fn"}                                                                                                                                                                                                    
   n                                                                                                                                                                    244                 228                                                                                                 217                                                   108
   LSM                                                                                                                                                                  1.5                 1.1                                                                                                 1.3                                                   0.7
   SE                                                                                                                                                                   0.14                0.15                                                                                                0.15                                                  0.22
  Treatment difference for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                                                                                                                                  
   LSM (95% CI)                                                                                                                                                         NA                  0.41 (0.01, 0.81)                                                                                   0.20 (−0.21, 0.60)                                    0.73 (0.22, 1.23)
   *P*-value                                                                                                                                                            NA                  0.0425[b](#tfn13-copd-13-2969){ref-type="table-fn"},[c](#tfn14-copd-13-2969){ref-type="table-fn"}   0.3379                                                0.0048[b](#tfn13-copd-13-2969){ref-type="table-fn"},[c](#tfn14-copd-13-2969){ref-type="table-fn"}
  Change from baseline in SGRQ total score at Week 24                                                                                                                                                                                                                                                                                                 
   n                                                                                                                                                                    489                 412                                                                                                 415                                                   196
   LSM                                                                                                                                                                  −5.3                −3.7                                                                                                −5.6                                                  −0.9
   SE                                                                                                                                                                   0.54                0.59                                                                                                0.59                                                  0.86
  Treatment difference for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                                                                                                                                  
   LSM (95% CI)                                                                                                                                                         NA                  −1.62 (−3.19, −0.05)                                                                                0.30 (−1.27, 1.87)                                    −4.40 (−6.39, −2.41)
   *P*-value                                                                                                                                                            NA                  0.0427[b](#tfn13-copd-13-2969){ref-type="table-fn"}                                                 0.7084                                                \<0.0001[b](#tfn13-copd-13-2969){ref-type="table-fn"}
  Change from baseline in SGRQ total score at Week 24 (symptomatic population)[c](#tfn14-copd-13-2969){ref-type="table-fn"}                                                                                                                                                                                                                           
   n                                                                                                                                                                    220                 202                                                                                                 189                                                   92
   LSM                                                                                                                                                                  −6.9                −3.8                                                                                                −7.8                                                  −1.6
   SE                                                                                                                                                                   0.88                0.91                                                                                                0.95                                                  1.37
  Treatment difference for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                                                                                                                                  
   LSM (95% CI)                                                                                                                                                         NA                  −3.10 (−5.59, −0.61)                                                                                0.89 (−1.65, 3.44)                                    −5.33 (−8.52, −2.14)
   *P*-value                                                                                                                                                            NA                  0.0148[b](#tfn13-copd-13-2969){ref-type="table-fn"}                                                 0.4908                                                0.0011[b](#tfn13-copd-13-2969){ref-type="table-fn"}
  Change from baseline in mean daily rescue medication use over 24 weeks[d](#tfn15-copd-13-2969){ref-type="table-fn"} (puffs/day) (rescue medication user population)                                                                                                                                                                                 
   n                                                                                                                                                                    256                 225                                                                                                 232                                                   109
   LSM                                                                                                                                                                  −1.4                −0.6                                                                                                −1.0                                                  −0.4
   SE                                                                                                                                                                   0.13                0.14                                                                                                0.14                                                  0.21
  Treatment difference for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                                                                                                                                  
   LSM (95% CI)                                                                                                                                                         NA                  −0.77 (−1.16, −0.38)                                                                                −0.41 (−0.80, −0.03)                                  −0.98 (−1.47, −0.49)
   *P*-value                                                                                                                                                            NA                  0.0001[b](#tfn13-copd-13-2969){ref-type="table-fn"}                                                 0.0345[e](#tfn16-copd-13-2969){ref-type="table-fn"}   \<0.0001[b](#tfn13-copd-13-2969){ref-type="table-fn"}

**Notes:**

TDI focal score over 24 weeks was based on assessments at Weeks 4, 8, 12, 16, 20, and 24.

Statistically significant/superior.

The symptomatic population was defined as patients in the ITT population with a COPD assessment test score ≥15 at baseline (screening).

The rescue medication user population was defined as all patients in the ITT population with the mean baseline rescue albuterol sulfate use of ≥1 puff/day.

Nominally significant (ie, *P*\<0.05 but not statistically significant due to procedure to control Type I error).

**Abbreviations:** FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; ITT, intent-to-treat; LSM, least squares mean; MDI, metered dose inhaler; NA, not applicable; SE, standard error; SGRQ, St George's Respiratory Questionnaire; TDI, Transition Dyspnea Index.

###### 

Responder analyses for MCID of secondary, patient-reported outcome endpoints (ITT population)

                                                                                                                                           GFF MDI 18/9.6 μg   GP MDI 18 μg                                          FF MDI 9.6 μg       Placebo MDI
  ---------------------------------------------------------------------------------------------------------------------------------------- ------------------- ----------------------------------------------------- ------------------- -------------------------------------------------------
  **Proportion of patients achieving the MCID threshold[a](#tfn19-copd-13-2969){ref-type="table-fn"}**                                                                                                                                   
  ≥1 unit improvement in TDI focal score over 24 weeks                                                                                                                                                                                   
   n                                                                                                                                       548                 474                                                   477                 235
   Responders, n (%)                                                                                                                       313 (57.11)         223 (47.14)                                           256 (53.73)         88 (37.19)
  Treatment comparison for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                     
   OR (95% CI)                                                                                                                             NA                  1.49 (1.17, 1.91)                                     1.15 (0.90, 1.47)   2.25 (1.64, 3.08)
   *P*-value                                                                                                                               NA                  0.0015[b](#tfn20-copd-13-2969){ref-type="table-fn"}   0.2785              \<0.0001[b](#tfn20-copd-13-2969){ref-type="table-fn"}
  ≥1 unit improvement in TDI focal score over 24 weeks (symptomatic population)[c](#tfn21-copd-13-2969){ref-type="table-fn"}                                                                                                             
   n                                                                                                                                       255                 239                                                   228                 117
   Responders, n (%)                                                                                                                       137 (53.80)         92 (38.49)                                            115 (50.38)         43 (36.70)
  Treatment comparison for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                     
   OR (95% CI)                                                                                                                             NA                  1.86 (1.30, 2.66)                                     1.15 (0.80, 1.64)   2.01 (1.28, 3.15)
   *P*-value                                                                                                                               NA                  0.0007[b](#tfn20-copd-13-2969){ref-type="table-fn"}   0.4540              0.0024[b](#tfn20-copd-13-2969){ref-type="table-fn"}
  ≥4 unit improvement from baseline in SGRQ total score at Week 24                                                                                                                                                                       
   n                                                                                                                                       549                 474                                                   480                 235
   Responders, n (%)                                                                                                                       256 (46.31)         193 (40.51)                                           219 (46.19)         81 (33.06)
  Treatment comparison for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                     
   OR (95% CI)                                                                                                                             NA                  1.27 (0.98, 1.63)                                     1.00 (0.78, 1.29)   1.75 (1.27, 2.41)
   *P*-value                                                                                                                               NA                  0.0669                                                0.9696              0.0007[b](#tfn20-copd-13-2969){ref-type="table-fn"}
  ≥4 unit improvement from baseline in SGRQ total score at Week 24 (symptomatic population)[c](#tfn21-copd-13-2969){ref-type="table-fn"}                                                                                                 
   n                                                                                                                                       255                 239                                                   229                 117
   Responders, n (%)                                                                                                                       125 (48.78)         100 (41.78)                                           112 (49.50)         35 (28.80)
  Treatment comparison for GFF MDI vs monocomponents and placebo MDI                                                                                                                                                                     
   OR (95% CI)                                                                                                                             NA                  1.33 (0.93, 1.90)                                     0.97 (0.68, 1.39)   2.35 (1.47, 3.77)
   *P*-value                                                                                                                               NA                  0.1229                                                0.8757              0.0004[b](#tfn20-copd-13-2969){ref-type="table-fn"}

**Notes:** Percentages are based on a logistic regression model with TDI or SGRQ response as a binary response (response/no response). Relevant baseline value (BDI or SGRQ) and reversibility to albuterol sulfate were continuous covariates, and treatment was a categorical covariate.

Validated thresholds for the MCID for each endpoint were used.[@b34-copd-13-2969]

Statistically significant/superior.

The symptomatic population was defined as patients in the ITT population with a COPD assessment test score of ≥15 at baseline (screening).

**Abbreviations:** BDI, Baseline Dyspnea Index; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; ITT, intent-to-treat; MCID, minimum clinically important difference; MDI, metered dose inhaler; SGRQ, St George's Respiratory Questionnaire; TDI, Transition Dyspnea Index.

###### 

Summary of AEs (safety population)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                         GFF MDI 18/9.6 μg\   GP MDI 18 μg\   FF MDI 9.6 μg\   Placebo MDI\
                                                                                                         (n=551)              (n=474)         (n=480)          (n=235)
  ------------------------------------------------------------------------------------------------------ -------------------- --------------- ---------------- --------------
  TEAEs, n (%)                                                                                                                                                 

   Patients with ≥1 TEAE                                                                                 306 (55.5)           250 (52.7)      256 (53.3)       131 (55.7)

   Patients with TEAEs related[a](#tfn23-copd-13-2969){ref-type="table-fn"} to study treatment           55 (10.0)            51 (10.8)       46 (9.6)         23 (9.8)

   Patients with serious TEAEs                                                                           53 (9.6)             34 (7.2)        40 (8.3)         19 (8.1)

   Patients with serious TEAEs related[a](#tfn23-copd-13-2969){ref-type="table-fn"} to study treatment   3 (0.5)              4 (0.8)         4 (0.8)          2 (0.9)

   Patients with TEAEs leading to early discontinuation                                                  27 (4.9)             25 (5.3)        24 (5.0)         10 (4.3)

   Deaths (all cause) during treatment period                                                            1 (0.2)              1 (0.2)         1 (0.2)          1 (0.4)

   Deaths (all cause) during treatment period +14 days                                                   1 (0.2)              1 (0.2)         1 (0.2)          1 (0.4)

  AEs occurring in ≥2% of patients in any treatment arm (preferred term), n (%)                                                                                

   Viral upper respiratory tract infection                                                               50 (9.1)             44 (9.3)        46 (9.6)         16 (6.8)

   Upper respiratory tract infection                                                                     37 (6.7)             33 (7.0)        29 (6.0)         20 (8.5)

   COPD[b](#tfn24-copd-13-2969){ref-type="table-fn"}                                                     16 (2.9)             12 (2.5)        13 (2.7)         7 (3.0)

   Headache                                                                                              15 (2.7)             11 (2.3)        10 (2.1)         3 (1.3)

   Hypertension                                                                                          16 (2.9)             6 (1.3)         3 (0.6)          8 (3.4)

   Cough                                                                                                 13 (2.4)             10 (2.1)        8 (1.7)          2 (0.9)

   Dyspnea                                                                                               11 (2.0)             6 (1.3)         7 (1.5)          7 (3.0)

   Back pain                                                                                             15 (2.7)             7 (1.5)         5 (1.0)          1 (0.4)

   Dizziness                                                                                             8 (1.5)              12 (2.5)        4 (0.8)          1 (0.4)

   Pneumonia                                                                                             9 (1.6)              5 (1.1)         5 (1.0)          6 (2.6)

   Bronchitis                                                                                            4 (0.7)              8 (1.7)         6 (1.3)          5 (2.1)

   Pharyngitis                                                                                           11 (2.0)             3 (0.6)         4 (0.8)          0
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Related = possibly, probably, or definitely related in the opinion of the investigator.

Worsening of COPD defined as a COPD exacerbation since the patient's last visit. COPD exacerbations were only recorded as an AE if they were considered to be a serious TEAE.

**Abbreviations:** AE, adverse event; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; MDI, metered dose inhaler; TEAE, treatment-emergent AE.
